Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene

@article{Tonini2006SulfonylureaTO,
  title={Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene},
  author={Giorgio Tonini and Carla Bizzarri and Riccardo Bonfanti and Maurizio Vanelli and Franco Cerutti and Elena Faleschini and Franco Meschi and Francesco Prisco and Enzo Ciacco and Marco Cappa and Carlos Javier Torelli and Vittoria Cauvin and Stefano Tumini and Dario Iafusco and Fabrizio Barbetti},
  journal={Diabetologia},
  year={2006},
  volume={49},
  pages={2210-2213}
}
To the Editor, Activating missense mutations in the gene encoding potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11) represent the most common cause (40 to 64%, depending on populations) of permanent neonatal diabetes mellitus in patients diagnosed in the first 6 months of life [1, 2]. In addition, KCNJ11 activating mutations can lead to transient/relapsing neonatal diabetes [3, 4]. The KCNJ11 gene encodes the pore-forming subunit (also known as KIR6.2) of the pancreatic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Activating mutations in the ATP-sensitive potassium channel subunit Kir6.2 gene are associated with permanent neonatal diabetes

  • AL Gloyn, ER Pearson, JF Antcliff
  • N Engl J Med
  • 2004
3 Excerpts

Similar Papers

Loading similar papers…